SEC 13F Intelligence

Rhenman & Partners Asset Management AB / VRTX

Rhenman & Partners Asset Management AB’s Vertex Pharmaceuticals Inc Position

Does Rhenman & Partners Asset Management AB own Vertex Pharmaceuticals Inc (VRTX)? Yes — 43.5K shares worth $19M (+2.40% of its 13F portfolio) as of Q1 2026, up from 34.3K shares the prior filed quarter.

Position Value
$19M
Q1 2026
Shares
43.5K
% of Portfolio
+2.40%
Quarters Held
30
currently held

Position History VRTX

Reported value by quarter
Q4 ’18: $22MQ4 ’18Q1 ’19: $27MQ2 ’19: $34MQ3 ’19: $32MQ4 ’19: $35MQ4 ’19Q1 ’20: $27MQ2 ’20: $40MQ3 ’20: $30MQ4 ’20: $27MQ4 ’20Q1 ’21: $36MQ2 ’21: $44MQ3 ’21: $30MQ4 ’21: $37MQ4 ’21Q1 ’22: $23MQ2 ’22: $27MQ3 ’22: $30MQ4 ’22: $23MQ4 ’22Q1 ’23: $26MQ2 ’23: $22MQ3 ’23: $27MQ4 ’23: $39MQ4 ’23Q1 ’24: $24MQ2 ’24: $25MQ3 ’24: $22MQ4 ’24: $20MQ4 ’24Q1 ’25: $32MQ2 ’25: $27MQ3 ’25: $18MQ4 ’25: $16MQ4 ’25Q1 ’26: $19Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202643.5K$19M+2.40%
Q4 202534.3K$16M+1.45%
Q3 202547.0K$18M+2.03%
Q2 202561.5K$27M+3.46%
Q1 202566.8K$32M+3.72%
Q4 202450.0K$20M+2.07%
Q3 202447.8K$22M+1.80%
Q2 202454.0K$25M+2.43%
Q1 202456.5K$24M+2.24%
Q4 202395.0K$39M+3.86%
Q3 202376.5K$27M+2.87%
Q2 202363.5K$22M+2.36%
Q1 202383.5K$26M+2.86%
Q4 202280.0K$23M+2.41%
Q3 202296.0K$30M+3.14%
Q2 202295.0K$27M+3.04%
Q1 202289.5K$23M+2.30%
Q4 2021165.0K$37M+2.44%
Q3 2021165.0K$30M+2.10%
Q2 2021215.9K$44M+2.95%
Q1 2021168.4K$36M+2.52%
Q4 2020115.0K$27M+2.22%
Q3 2020110.0K$30M+2.66%
Q2 2020137.5K$40M+4.31%
Q1 2020115.0K$27M+3.83%
Q4 2019160.0K$35M+3.84%
Q3 2019186.0K$32M+3.95%
Q2 2019185.2K$34M+3.74%
Q1 2019144.4K$27M+3.11%
Q4 2018132.4K$22M+2.51%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Rhenman & Partners Asset Management AB’s full portfolio or all institutional holders of VRTX.